Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by $2.20, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $232.80 -0.79%
Financial Fact:
Income from operations: 136.25M
Today's EPS Names:
KELYA, ROX, KEEL, More
Financial Fact:
Income from operations: 136.25M
Today's EPS Names:
KELYA, ROX, KEEL, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $8.13, $2.20 better than the analyst estimate of $5.93. Revenue for the quarter came in at $1.13 billion versus the consensus estimate of $1.11 billion.
GUIDANCE:
Jazz Pharmaceuticals sees Q4 2025 revenue of $4.175-4.275 billion, versus the consensus of $4.221 billion.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Becton Dickinson (BDX) Tops Q4 EPS by 8c; Offers Guidance
- Assurant (AIZ) PT Raised to $345 at Keefe, Bruyette & Woods
- McDonald's (MCD) PT Raised to $280 at Bernstein SocGen Group
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
